Ost-müük Genprex, Inc. - GNPX CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.0418 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 0.815 |
Avatud* | 0.8278 |
Aastane muutus* | -63.04% |
Päeva ulatus* | 0.8081 - 0.8924 |
52 nädala ulatus | 0.74-2.67 |
Keskmine maht (10 päeva) | 372.32K |
Keskmine maht (3 kuud) | 8.54M |
Turukapitalisatsioon | 43.66M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 51.97M |
Tulu | N/A |
EPS | -0.47 |
Dividendid (% kasumist) | N/A |
Beeta | -0.34 |
Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 0.8763 | 0.0682 | 8.44% | 0.8081 | 0.8924 | 0.8078 |
Mar 23, 2023 | 0.8150 | -0.0130 | -1.57% | 0.8280 | 0.8544 | 0.7941 |
Mar 22, 2023 | 0.7960 | -0.0021 | -0.26% | 0.7981 | 0.8149 | 0.7775 |
Mar 21, 2023 | 0.7603 | 0.0151 | 2.03% | 0.7452 | 0.7772 | 0.7283 |
Mar 20, 2023 | 0.7274 | -0.0656 | -8.27% | 0.7930 | 0.7931 | 0.7210 |
Mar 17, 2023 | 0.7449 | -0.0700 | -8.59% | 0.8149 | 0.8149 | 0.7283 |
Mar 16, 2023 | 0.7870 | -0.0179 | -2.22% | 0.8049 | 0.8091 | 0.7558 |
Mar 15, 2023 | 0.7945 | -0.0751 | -8.64% | 0.8696 | 0.8781 | 0.7677 |
Mar 14, 2023 | 0.8400 | -0.1078 | -11.37% | 0.9478 | 0.9541 | 0.8400 |
Mar 13, 2023 | 0.8952 | 0.0272 | 3.13% | 0.8680 | 0.9172 | 0.8505 |
Mar 10, 2023 | 0.8868 | -0.1109 | -11.12% | 0.9977 | 1.0077 | 0.8779 |
Mar 9, 2023 | 0.9977 | -0.0299 | -2.91% | 1.0276 | 1.0376 | 0.9937 |
Mar 8, 2023 | 1.0276 | -0.0699 | -6.37% | 1.0975 | 1.0975 | 1.0077 |
Mar 7, 2023 | 1.0276 | -0.0699 | -6.37% | 1.0975 | 1.1075 | 1.0176 |
Mar 6, 2023 | 1.0875 | -0.0200 | -1.81% | 1.1075 | 1.1175 | 1.0875 |
Mar 3, 2023 | 1.1175 | -0.0299 | -2.61% | 1.1474 | 1.1574 | 1.0875 |
Mar 2, 2023 | 1.1274 | -0.0100 | -0.88% | 1.1374 | 1.1574 | 1.0576 |
Mar 1, 2023 | 1.1274 | -0.1197 | -9.60% | 1.2471 | 1.2671 | 1.1174 |
Feb 28, 2023 | 1.2671 | 0.1597 | 14.42% | 1.1074 | 1.3370 | 1.1074 |
Feb 27, 2023 | 1.1174 | -0.1098 | -8.95% | 1.2272 | 1.2272 | 1.0975 |
Genprex, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Tulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 19.6008 | 17.9616 | 10.6827 | 12.3635 | 3.31235 |
Müük/Üldine/admin kulud, kokku | 10.9705 | 10.6359 | 8.7026 | 11.3862 | 3.01917 |
Uuringud ja arendus | 8.60775 | 7.30292 | 1.96701 | 0.97143 | 0.28993 |
Depreciation / Amortization | 0.02253 | 0.02278 | 0.01307 | 0.00589 | 0.00324 |
Tulud majandustegevusest | -19.6008 | -17.9616 | -10.6827 | -12.3635 | -3.31235 |
Netotulu enne makse | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
Netotulu pärast makse | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
Netotulu enne erikulusid | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
Netotulu | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
Arvestatav tulu, v a erikulud | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
Arvestatav tulu, koos erikuludega | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
Jaotuse korrigeerimine | |||||
Jaotamisele kuuluv netotulu | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
Keskmine jaotamisele kuuluv aktsia kohta | 47.0973 | 35.5229 | 16.027 | 13.771 | 13.035 |
Jaotatav EPS, v a erakorralised kulud | -0.41607 | -0.5051 | -0.6648 | -0.89843 | -0.25425 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Jaotamisele kuuluv normaal-EPS | -0.41607 | -0.5051 | -0.6648 | -0.89843 | -0.25425 |
Intressitulud (kulu), muud tulud, neto | 0.00513 | 0.01881 | 0.02791 | -0.0088 | -0.00181 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Tulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 5.72336 | 5.68292 | 3.43893 | 3.98722 | 6.4917 |
Müük/Üldine/admin kulud, kokku | 3.8558 | 2.19563 | 2.00044 | 2.4581 | 4.31631 |
Uuringud ja arendus | 1.86084 | 3.48033 | 1.432 | 1.52628 | 2.16914 |
Depreciation / Amortization | 0.00673 | 0.00696 | 0.00649 | 0.00285 | 0.00624 |
Tulud majandustegevusest | -5.72336 | -5.68292 | -3.43893 | -3.98722 | -6.4917 |
Intressitulud (kulu), muud tulud, neto | 0.00088 | 0.00099 | 0.00106 | 0.0011 | 0.00198 |
Netotulu enne makse | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
Netotulu pärast makse | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
Netotulu enne erikulusid | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
Netotulu | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
Arvestatav tulu, v a erikulud | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
Arvestatav tulu, koos erikuludega | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
Jaotamisele kuuluv netotulu | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
Keskmine jaotamisele kuuluv aktsia kohta | 47.8796 | 47.8353 | 47.6124 | 47.3725 | 45.5461 |
Jaotatav EPS, v a erakorralised kulud | -0.11952 | -0.11878 | -0.07221 | -0.08414 | -0.14249 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.11952 | -0.11878 | -0.07221 | -0.08414 | -0.14249 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Käibevarad kokku | 39.1402 | 27.7044 | 2.97664 | 8.84707 | 0.19357 |
Raha ja lühiajalised investeeringud | 38.6289 | 27.3197 | 2.00249 | 8.60092 | 0.16125 |
Cash | 38.6289 | 27.3197 | 2.00249 | 8.60092 | 0.16125 |
Prepaid Expenses | 0.51135 | 0.38455 | 0.17172 | 0.23685 | 0.02348 |
Total Assets | 42.8623 | 31.3672 | 3.53423 | 9.26896 | 1.25954 |
Property/Plant/Equipment, Total - Net | 0.04861 | 0.03944 | 0.04465 | 0.02435 | 0.0078 |
Intangibles, Net | 3.66476 | 3.61267 | 0.4912 | 0.37945 | 0.29857 |
Other Long Term Assets, Total | 0.00869 | 0.01074 | 0.02173 | 0.01809 | 0.75959 |
Total Current Liabilities | 1.5853 | 0.45072 | 0.51068 | 0.38782 | 0.83096 |
Accounts Payable | 0.9732 | 0.19297 | 0.43626 | 0.29507 | 0.62907 |
Notes Payable/Short Term Debt | 0 | 0 | 0.07443 | 0.09275 | 0.20189 |
Total Liabilities | 1.5853 | 0.45072 | 0.51068 | 0.38782 | 0.83096 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 41.277 | 30.9165 | 3.02355 | 8.88114 | 0.42857 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.04787 | 0.04312 | 0.01926 | 0.01524 | 0.01172 |
Additional Paid-In Capital | 119.247 | 89.2956 | 43.4837 | 38.6906 | 17.8692 |
Retained Earnings (Accumulated Deficit) | -78.0179 | -58.4222 | -40.4795 | -29.8247 | -17.4524 |
Total Liabilities & Shareholders’ Equity | 42.8623 | 31.3672 | 3.53423 | 9.26896 | 1.25954 |
Total Common Shares Outstanding | 47.8747 | 43.1177 | 19.2638 | 15.2392 | 13.035 |
Laekumata arved, neto | 0 | 0.00013 | 0.00066 | 0.0093 | 0.00884 |
Accounts Receivable - Trade, Net | 0 | 0.00013 | 0.00066 | 0.0093 | 0.00884 |
Total Inventory | 0.80178 | ||||
Other Current Liabilities, Total | 0.6121 | 0.25776 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 35.7031 | 39.1402 | 45.6447 | 48.0615 | 50.3777 |
Raha ja lühiajalised investeeringud | 34.5553 | 38.6289 | 42.0205 | 44.2435 | 47.0687 |
Cash | 34.5553 | 38.6289 | 42.0205 | 44.2435 | 47.0687 |
Laekumata arved, neto | 0.03217 | 0 | 0.00013 | 0.00013 | 0.00013 |
Accounts Receivable - Trade, Net | 0.03217 | 0 | 0.00013 | 0.00013 | 0.00013 |
Total Inventory | 2.87505 | 3.06236 | 3.1079 | ||
Prepaid Expenses | 1.1156 | 0.51135 | 0.74903 | 0.7556 | 0.201 |
Total Assets | 39.4094 | 42.8623 | 46.3272 | 48.7314 | 51.0365 |
Property/Plant/Equipment, Total - Net | 0.04188 | 0.04861 | 0.04434 | 0.03949 | 0.0373 |
Intangibles, Net | 3.65444 | 3.66476 | 0.62736 | 0.61967 | 0.6107 |
Other Long Term Assets, Total | 0.01 | 0.00869 | 0.01074 | 0.01074 | 0.01074 |
Total Current Liabilities | 2.38482 | 1.5853 | 1.16189 | 1.04722 | 0.61363 |
Accounts Payable | 1.25298 | 0.9732 | 0.59194 | 0.36979 | 0.33897 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.13184 | 0.6121 | 0.56995 | 0.67743 | 0.27466 |
Total Liabilities | 2.38482 | 1.5853 | 1.16189 | 1.04722 | 0.61363 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 37.0246 | 41.277 | 45.1653 | 47.6842 | 50.4229 |
Common Stock | 0.04788 | 0.04787 | 0.0478 | 0.04752 | 0.04732 |
Additional Paid-In Capital | 120.717 | 119.247 | 117.453 | 116.535 | 115.287 |
Retained Earnings (Accumulated Deficit) | -83.7403 | -78.0179 | -72.3359 | -68.8981 | -64.9119 |
Total Liabilities & Shareholders’ Equity | 39.4094 | 42.8623 | 46.3272 | 48.7314 | 51.0365 |
Total Common Shares Outstanding | 47.8797 | 47.8747 | 47.8036 | 47.5229 | 47.3148 |
Other Equity, Total | 0 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
Raha majandustegevusest | -14.2849 | -13.9351 | -6.91872 | -6.84653 | -2.17159 |
Raha majandustegevusest | 0.02253 | 0.02278 | 0.01307 | 0.00589 | 0.00324 |
Mittelikviidsed varad | 4.27821 | 4.24619 | 3.52998 | 5.43538 | 1.32389 |
Muutused tööjõus | 1.00995 | -0.26128 | 0.19299 | 0.08454 | -0.18457 |
Tulu investeeringutelt | -0.0838 | -2.33725 | -0.9469 | -0.10332 | -0.06342 |
Kapitalikulutused | -0.07244 | -0.12799 | -0.14512 | -0.10332 | -0.06342 |
Rahavood investeeringutelt | 25.6779 | 41.5895 | 1.26719 | 15.3895 | 0.79397 |
Aktsiate emiteerimine (tagasiost), neto | 25.6779 | 41.5895 | 1.26719 | 15.3895 | 0.79397 |
Rahaline kogumuutus | 11.3092 | 25.3172 | -6.59843 | 8.43967 | -1.44104 |
Muud rahavood investeeringutelt, kokku | -0.01136 | -2.20926 | -0.80178 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -5.72248 | -19.5956 | -13.9137 | -10.4758 | -6.48971 |
Cash From Operating Activities | -4.08386 | -14.2849 | -11.0668 | -8.43209 | -5.46528 |
Cash From Operating Activities | 0.00673 | 0.02253 | 0.01558 | 0.00909 | 0.00624 |
Non-Cash Items | 1.47011 | 4.27821 | 2.48457 | 1.8092 | 0.67174 |
Cash Taxes Paid | 0 | 0 | |||
Cash Interest Paid | 0 | 0 | |||
Changes in Working Capital | 0.16179 | 1.00995 | 0.34669 | 0.22545 | 0.34645 |
Cash From Investing Activities | 0.01032 | -0.0838 | 0.08978 | -0.07851 | -0.11003 |
Capital Expenditures | -0.00184 | -0.07244 | -0.04622 | -0.02719 | -0.10077 |
Other Investing Cash Flow Items, Total | 0.01216 | -0.01136 | 0.136 | -0.05132 | -0.00926 |
Cash From Financing Activities | 0 | 25.6779 | 25.6779 | 25.4344 | 25.3243 |
Issuance (Retirement) of Stock, Net | 0 | 25.6779 | 25.6779 | 25.4344 | 25.3243 |
Net Change in Cash | -4.07354 | 11.3092 | 14.7008 | 16.9238 | 19.749 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.5144 | 1826600 | 1043 | 2022-12-31 | LOW |
Varner (John Rodney) | Individual Investor | 2.2348 | 1161535 | 625000 | 2023-02-18 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.069 | 555623 | 2408 | 2022-12-31 | LOW |
Confer (Ryan M.) | Individual Investor | 0.8379 | 435499 | 245000 | 2023-02-18 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8314 | 432137 | -8520 | 2022-12-31 | LOW |
Berger (Mark Stanley) | Individual Investor | 0.4714 | 245000 | 245000 | 2023-02-18 | |
Vaczy (Catherine M) | Individual Investor | 0.4714 | 245000 | 245000 | 2023-02-18 | |
Kumar (Hermant) | Individual Investor | 0.3848 | 200000 | 200000 | 2023-02-18 | |
UBS Financial Services, Inc. | Investment Advisor | 0.3089 | 160546 | -119788 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2496 | 129739 | 0 | 2022-12-31 | LOW |
Cypress Capital, LLC | Investment Advisor | 0.1924 | 100000 | 0 | 2022-12-31 | MED |
Verus Capital Partners, LLC | Investment Advisor | 0.1703 | 88500 | -2000 | 2022-12-31 | MED |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1663 | 86430 | 11029 | 2022-12-31 | LOW |
Group One Trading, L.P. | Research Firm | 0.1161 | 60354 | -79668 | 2022-12-31 | HIGH |
Silvercrest Asset Management Group LLC | Investment Advisor/Hedge Fund | 0.1077 | 56000 | 0 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.1056 | 54900 | -18656 | 2022-12-31 | HIGH |
IHT Wealth Management, LLC | Investment Advisor | 0.1008 | 52375 | 0 | 2022-12-31 | LOW |
Staley Capital Advisers, Inc. | Hedge Fund | 0.0962 | 50000 | 0 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 0.0687 | 35688 | 21508 | 2022-12-31 | HIGH |
StoneX Group Inc. | Research Firm | 0.0676 | 35150 | 0 | 2022-12-31 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Genprex, Inc. Company profile
Ettevõttest Genprex, Inc.
Genprex, Inc. on kliinilises staadiumis geeniteraapia ettevõte, mis keskendub vähi ja diabeedi ravimeetodite väljatöötamisele. Ettevõtte peamine vähiravimikandidaat, REQORSA immunogeenravi ravim (ka GPX-001), töötatakse välja mitteväikerakk-kopsuvähi (NSCLC) raviks. REQORSA toimeaine on TUSC2 geeni ekspresseeriv plasmiid, mis on kapseldatud DOTAP-kolesterooli nanoosakesse. TUSC2 on kasvaja supressorgeen, millel on nii kasvaja surmav (apoptoosi kaudu) kui ka immunomoduleeriv toime. Ettevõte kasutab oma ONCOPREX nanoosakeste manustamissüsteemi TUSC2 geeni ekspresseeriva plasmiidi viimiseks vähirakkudesse. Ettevõtte diabeedi geeniteraapia, mida nimetatakse ka GPX-002, on kavandatud toimima, muutes kõhunäärme alfa-rakud funktsionaalseteks beetarakudeks, mis suudavad toota insuliini, kuid on piisavalt erinevad beetarakkudest, et vältida organismi immuunsüsteemi.
Industry: | Bio Therapeutic Drugs |
Suite 3.322
1601 Trinity Street, Bldg. B
78712
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com